 |
| Date | Title | | | 01/27/12 | FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 Diabetes| Provides Glycemic Control in a Once-Weekly Dose
SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON™ (exenatide extended-release for injectable suspension) – the first once-weekly treatment for type 2 diabetes. BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to ... |
|  | | 01/09/12 | Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates| 2012 Corporate Priorities Unveiled at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.
In a presentation at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, Amylin President and Chief Executive Officer Daniel M. Bradbury highlighted steps the compan... |
| | | 01/03/12 | Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference|
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 5:00 p.m. ET / 2:00 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a r... |
| | | 11/23/11 | Amylin Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Healthcare Conference| SAN DIEGO, Nov. 23, 2011 /PRNewswire via COMTEX/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 23rd Annual Piper Jaffray Health Care Conference in New York on Wednesday, November 30, 2011 at 1:00 p.m. ET/10:00 a.m. PT. Mark Foletta, Senior Vice President and Chief Financial Officer, Amylin Pharmaceuticals, will provide a corporate overview.
The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a r... |
| |
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
